Sugi Predict

Sugi Predict / Compounds / SCHEMBL25752562

SCHEMBL25752562

SCHEMBL25752562

Cn1cc(NC(=O)OC(C)(C)C)c2c(=O)n(C3CC3)ccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 1/20 0.36
▸ OPRD1 P41143 1/20 0.36
▸ OGFRL1 Q5TC84 1/20 0.36
▸ PRKCG P05129 1/20 0.36
▸ PRKCB P05771 1/20 0.36
▸ PRKCA P17252 1/20 0.36
▸ PRKCH P24723 1/20 0.36
▸ PRKCE Q02156 1/20 0.36
▸ PRKCD Q05655 1/20 0.36
▸ CNR2 P34972 1/20 0.35
▸ PIK3CA P42336 2/20 0.33
▸ PRKDC P78527 2/20 0.33
▸ MTOR P42345 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ ABL1 P00519 4/20 0.33
▸ BRD4 O60885 2/20 0.33
▸ BRD2 P25440 2/20 0.33
▸ BRD3 Q15059 2/20 0.33
▸ CREBBP Q92793 1/20 0.33
▸ PIK3CD O00329 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25752642 0.96 OPRM1 (0.39) OPRM1OPRD1OGFRL1PRKCGPRKCB
SCHEMBL30895094 0.89 P2RX7 (0.35) OPRM1OPRD1OGFRL1AAK1
SCHEMBL30895158 0.89 P2RX7 (0.35) OPRM1OPRD1OGFRL1AAK1
SCHEMBL25670291 0.85 CNR2 (0.39) CNR2PIK3CAPRKDCABL1BRD4
SCHEMBL27199323 0.83 ALDH1A1 (0.34) KMT2AIRAK4RXFP1
SCHEMBL30895101 0.82 DRD2 (0.38) OPRM1OPRD1OGFRL1CNR2PIK3CA
SCHEMBL25670769 0.80 CNR2 (0.42) CNR2BRD4ELANERXFP1
SCHEMBL25750429 0.80 ELANE (0.38) CNR2PIK3CAPRKDCMTORABL1
SCHEMBL27199346 0.79 ALDH1A1 (0.38) KMT2ARXFP1
SCHEMBL25752652 0.78 CNR2 (0.39) CNR2ELANERXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 — — CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 OPRM1 4435/4885OPRD1 4532/4885OGFRL1 3005/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 OPRM1 4435/4885OPRD1 4532/4885OGFRL1 3005/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 OPRM1 4435/4885OPRD1 4532/4885OGFRL1 3005/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.